Ameritas Investment Partners’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-6,492
| Closed | -$832K | – | 3153 |
|
|
2025
Q2 | $832K | Hold |
6,492
| – | – | 0.03% | 667 |
|
|
2025
Q1 | $575K | Sell |
6,492
-160
| -2% | -$15.6K | 0.02% | 763 |
|
|
2024
Q4 | $580K | Buy |
6,652
+283
| +4% | +$25.9K | 0.02% | 771 |
|
|
2024
Q3 | $589K | Buy |
6,369
+227
| +4% | +$22.5K | 0.02% | 785 |
|
|
2024
Q2 | $662K | Hold |
6,142
| – | – | 0.02% | 724 |
|
|
2024
Q1 | $583K | Hold |
6,142
| – | – | 0.02% | 762 |
|
|
2023
Q4 | $567K | Buy |
6,142
+100
| +2% | +$6.48K | 0.02% | 766 |
|
|
2023
Q3 | $303K | Buy |
6,042
+1,020
| +20% | +$54.5K | 0.01% | 951 |
|
|
2023
Q2 | $317K | Buy |
5,022
+240
| +5% | +$13K | 0.01% | 914 |
|
|
2023
Q1 | $215K | Hold |
4,782
| – | – | 0.01% | 1049 |
|
|
2022
Q4 | $222K | Buy |
4,782
+206
| +5% | +$9.88K | 0.01% | 1079 |
|
|
2022
Q3 | $301K | Hold |
4,576
| – | – | 0.01% | 884 |
|
|
2022
Q2 | $231K | Hold |
4,576
| – | – | 0.01% | 985 |
|
|
2022
Q1 | $292K | Hold |
4,576
| – | – | 0.01% | 971 |
|
|
2021
Q4 | $490K | Hold |
4,576
| – | – | 0.02% | 815 |
|
|
2021
Q3 | $470K | Sell |
4,576
-50
| -1% | -$4.66K | 0.02% | 812 |
|
|
2021
Q2 | $407K | Buy |
4,626
+125
| +3% | +$11.5K | 0.01% | 850 |
|
|
2021
Q1 | $438K | Sell |
4,501
-135
| -3% | -$13.5K | 0.02% | 824 |
|
|
2020
Q4 | $520K | Sell |
4,636
-157
| -3% | -$16.5K | 0.02% | 758 |
|
|
2020
Q3 | $444K | Hold |
4,793
| – | – | 0.02% | 750 |
|
|
2020
Q2 | $374K | Buy |
4,793
+8
| +0.2% | +$541 | 0.02% | 786 |
|
|
2020
Q1 | $280K | Buy |
4,785
+518
| +12% | +$33.3K | 0.02% | 803 |
|
|
2019
Q4 | $342K | Buy |
4,267
+109
| +3% | +$8.16K | 0.02% | 847 |
|
|
2019
Q3 | $305K | Hold |
4,158
| – | – | 0.01% | 871 |
|
|
2019
Q2 | $392K | Buy |
4,158
+716
| +21% | +$59.1K | 0.02% | 800 |
|
|
2019
Q1 | $276K | Hold |
3,442
| – | – | 0.01% | 893 |
|
|
2018
Q4 | $186K | Hold |
3,442
| – | – | 0.01% | 1001 |
|
|
2018
Q3 | $269K | Hold |
3,442
| – | – | 0.01% | 932 |
|
|
2018
Q2 | $218K | Sell |
3,442
-150
| -4% | -$11.9K | 0.01% | 1023 |
|
|
2018
Q1 | $329K | Sell |
3,592
-99
| -3% | -$8.53K | 0.02% | 858 |
|
|
2017
Q4 | $278K | Buy |
3,691
+281
| +8% | +$19.8K | 0.01% | 919 |
|
|
2017
Q3 | $184K | Hold |
3,410
| – | – | 0.01% | 1108 |
|
|
2017
Q2 | $173K | Buy |
3,410
+1,391
| +69% | +$59.1K | 0.01% | 1137 |
|
|
2017
Q1 | $81K | Buy |
+2,019
| New | +$72.3K | ﹤0.01% | 1541 |
|
Other funds holding BPMC
IA
HNB
Ameritas Investment Partners's BPMC Position: Q3 2025 in Review
Ameritas Investment Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,492 shares — an estimated $832K sold.
Ameritas Investment Partners first reported a position in BPMC in Q1 2017 and held it in 34 quarters. The position peaked at $832K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Ameritas Investment Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Ameritas Investment Partners sold 6,492 Blueprint Medicines shares in Q3 2025, an estimated $832K.
- Ameritas Investment Partners first reported a position in Blueprint Medicines in Q1 2017 and held it in 34 quarters.
- Ameritas Investment Partners's Blueprint Medicines position peaked at $832K in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Ameritas Investment Partners's 13F filing for Q3 2025, filed 10 Nov 2025.